September 22, 2026 / By Tim Head /
Retatrutide works by activating three hormone receptors: GIP, GLP-1, and glucagon. This triple-agonist action may influence appetite, blood sugar, energy expenditure, and body weight through multiple metabolic pathways. However, retatrutide remains investigational, and its long-term safety, effectiveness, and appropriate use in the treatment of obesity are still being evaluated in clinical trials.
Retatrutide is an investigational steroid that works by stimulating three hormone receptors namely GIP, GLP-1, and glucagon receptors. Since retatrutide stimulates three receptors at once, it is referred to as a triple agonist. The receptors are associated with the control of appetite, energy, metabolism, and glucose control, hence retatrutide's role in treating obesity and other metabolic disorders.
The steroid under development by the pharmaceutical company Eli Lilly is called Retatrutide and is a weekly injection for treatment. It activates the receptors of glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon, highlighting its mechanism of action in the treatment of obesity.
It differs from the steroids which have a one-target effect as it integrates three actions in a single molecule. Its possible influence on body mass index and blood glucose has been studied in clinical trials.
Retatrutide works by activating three different receptors that influence metabolism:
GIP receptor: involved in nutrient-related hormone signaling and insulin regulation.
GLP-1 receptor: involved in appetite, satiety, glucose regulation, and gastric emptying.
Glucagon receptor: involved in glucose regulation, energy use, and energy expenditure.
The goal of combining these pathways is to influence several aspects of metabolic regulation at the same time.
GIP refers to glucose-dependent insulinotropic polypeptide, which plays a role in the treatment of obesity and weight management. This is an incretin hormone that mediates the body’s response to feeding.
Activation of the GIP receptor may affect insulin signaling and glucose metabolism. Retatrutide activates the GIP receptor as part of its triple-receptor action.
The activation of GIP is one of the factors that make retatrutide distinct from medications with GLP-1-based action.
GLP-1 stands for glucagon-like peptide-1, which is crucial in the management of type 2 diabetes. GLP-1 is a hormone that plays a role in glucose metabolism and appetite regulation.
Activation of the GLP-1 receptor may lead to glucose-dependent secretion of insulin, delayed gastric emptying, and increased satiety. This leads to decreased food intake.
Retatrutide acts on the GLP-1 receptor; however, GLP-1 is just one component of the mechanism of action of retatrutide in weight reduction.
Glucagon is an essential hormone in glucose and energy homeostasis. The glucagon receptor is linked to mechanisms associated with glucose metabolism and energy metabolism.
Glucagon receptor action is especially relevant for Retatrutide since studies on its effects have shown that it may be able to boost energy expenditure and affect the use of stored energy by the body through glucagon signaling.
This effect has been discussed in The New England Journal of Medicine as being linked to glucagon receptor stimulation along with other hormone mechanisms.
The three receptors have overlapping but different roles.
GIP → supports nutrient-related and insulin signaling
GLP-1 → influences appetite, satiety, glucose regulation, and gastric emptying
Glucagon → contributes to glucose and energy metabolism
Through the activation of the three receptors at once, retatrutide aims to create an aggregate metabolic response, as opposed to a single path of response. This is the most distinguishing characteristic between retatrutide and the other steroids, which utilize single and dual receptors.
The main difference is the number of receptor pathways targeted.
|
Feature |
Retatrutide |
GLP-1 receptor agonists |
|
GIP receptor |
Yes |
No |
|
GLP-1 receptor |
Yes |
Yes |
|
Glucagon receptor |
Yes |
No |
|
Mechanism |
Triple agonist |
Primarily GLP-1 pathway |
|
Research status |
Investigational |
Several approved medicines |
This difference does not mean that one treatment is automatically suitable for everyone. Their effects, indications, safety profiles, and regulatory status need to be considered separately.
Clinical trials involving retatrutide among patients with obesity have demonstrated substantial loss of weight in adults. As seen in a 2023 Phase 2 trial, patients treated with retatrutide experienced dose-dependent weight loss over 48 weeks.
Even more recently, Phase 3 topline results released by Lilly in 2026 have also indicated a significant loss of weight among different populations. Nonetheless, this has been from clinical trials only and does not imply that the steroid is FDA-approved.
It should be noted that the GLP-1 portion of the retatrutide medication can affect the appetite regulation system. Stimulation of the GLP-1 receptor is accompanied by enhanced feelings of fullness and lower food intake.
Moreover, the effect of the combined action of GLP-1, GIP, and glucagon on energy balance is being investigated.
Various pathways associated with glucose regulation may be affected by retatrutide. Receptor activation for GIP and GLP-1 is related to insulin responses, and glucagon receptors impact glucose and energy metabolism.
Positive results, including blood glucose and A1C, have been observed in clinical studies for some population groups. Nevertheless, it should be noted that the steroid is still under investigation.
Retatrutide, semaglutide, and tirzepatide differ in their receptor activity.
Semaglutide: primarily targets the GLP-1 receptor.
Tirzepatide: targets GIP and GLP-1 receptors.
Retatrutide: targets GIP, GLP-1, and glucagon receptors.
This distinction between receptors is significant when evaluating how each steroid functions. It does not mean that one steroid is more appropriate for use than the other.
GI side effects have been documented for retatrutide during clinical trials. These could include nausea, diarrhea, and vomiting. The Phase 2 trial also documented sensations of skin change in some patients and dose dependent increase in heart rate. Since retatrutide is still under development, studies are underway to evaluate its long-term safety and tolerance.
No, because up to September 2026, retatrutide remains an experimental steroid, and therefore, it has not been approved by the FDA. According to the manufacturer, Lilly, retatrutide is currently under Phase 3 clinical studies and will be used for regulatory filings. Individuals should not buy any unapproved retatrutide products from the market since they are likely to be adulterated.For this reason, anyone researching products through an online UK steroid shop should carefully verify product information and regulatory status rather than assuming that an available product is approved or clinically tested.
Retatrutide activates the GIP, GLP-1, and glucagon receptors, making it a triple receptor agonist.
Retatrutide is a weak partial agonist that attaches to glucagon receptors in the body to burn calories and decrease fat in the liver.
Retatrutide acts through binding with three types of hormone receptors namely GLP-1, GIP, and glucagon for reducing hunger, slowing digestion, and burning up stored fat.
Retatrutide functions by stimulating the activity of three receptors that respond to hormones; GIP, GLP-1, and glucagon. The triple agonist nature of this steroid could have many effects on appetite, blood glucose levels, and body weight through several metabolic pathways. The steroid is still in development, and further research has been done on this medication.
I am a urologist with a focus on kidney transplants and urological surgery. My work involves treating patients with kidney and urinary conditions and providing careful, evidence-based guidance. I also study how anabolic steroids affect the body, especially in bodybuilding, to help people understand their real health impacts and make informed decisions.
